Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30% as Operating ...

Resumen detallado
YARTEMLEA Gross Sales: $41.8 million in Q3, up 30% from $32.2 million in Q2. YARTEMLEA Net Sales: $35.9 million in Q3, up 26% from $28.5 million in Q2. Gross-to-Net Deductions:…
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you discuss the pace of YARTEMLEA adoption from here, and how much utilization the New Technology Add-On Payment (NTAP) will drive in Q4? Are you seeing a noticeable change in utilization since the October 1 NTAP effective date? A: CEO Gregory Demopulos declined to guide Q4 results but said the growth momentum has continued into the fourth quarter. He noted that physicians and institutions are not yet widely aware of the NTAP award, and educating them is a current focus. Chief Commercial Officer Bill Woodman added that NTAP uptake is a learning process, and Omeros will highlight the program at its ASH booth.
Q: Where do you ultimately expect gross-to-net to settle as patients shift to the outpatient setting? A: CEO Gregory Demopulos said Omeros has not shared a target but is approaching the cap faster than anticipated. The increase from 11.5% to 14% was almost entirely due to 340B, which he called an encouraging signal of the shift from inpatient to outpatient. He noted the 340B discount is government-mandated and has no impact on ASP, and he offered a soft estimate that gross-to-net could approach the high-teens at some point.
Q: Can you talk about vial volume in the inpatient versus outpatient setting, and what average revenue per patient looks like now? A: CEO Gregory Demopulos declined to share the vial split but said outpatient use has meaningfully increased. He noted a shift toward twice-weekly dosing early in treatment, which likely ties to the outpatient shift. Average use in the study and expanded-access program was 8 to 10 vials per course, though some pediatric patients stayed on drug beyond a year because physicians were reluctant to stop given relapse concerns.
Q: With reimbursement and access largely buttoned up via NTAP, the J-code, and 340B clarity, will you be in a position to provide 2027 guidance?
Q: To confirm, you are actually cash…
Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)




